RNA
Atrium Therapeutics, Inc.
There isn't enough reported data to score RNA yet.
RNA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
RNA's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
RNA PE Valuation
RNA has no meaningful PE right now: it lost money over the past year.
RNA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect RNA's losses to grow, with revenue declining.
RNA Earnings Per Share
RNA Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -43% | N/A |
| Q2 2026 | -753% | N/A |
| Q1 2026 | -88% | N/A |
| Q4 2025 | -5592% | N/A |
RNA Free Cash Flow
RNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -69K shares |
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
RNA Net Leverage
RNA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.5 | Neutral |
| Stochastic | 7.6 | Oversold |
RNA's weekly RSI is 31 (neutral) and its Stochastic is 8 (oversold).
RNA PE vs Healthcare Sector
RNA has no meaningful PE right now: it lost money over the past year.
RNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.06 | 6.9% below |
| 20 week MA | $10.6 | 29% below |
RNA is in a downtrend: it's below all two of its weekly moving averages, and 29% below its 20-week average.
RNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $14.8 | $7.50 | -49% |
It's down 49% so far in 2026.